Transient prenatal ruxolitinib treatment suppresses astrogenesis during development and improves learning and memory in adult mice

Transient prenatal ruxolitinib treatment suppresses astrogenesis during development and improves learning and memory in adult mice

Show other versions (1)

Ruxolitinib is the first janus kinase 1 (JAK1) and JAK2 inhibitor that was approved by the United States Food and Drug Administration (FDA) agency for the treatment of myeloproliferative neoplasms. The drug targets the JAK/STAT signalling pathway, which is critical in regulating the gliogenesis proc...

Full description

Bibliographic Details
Main Authors: Abdullah, MA (Author), Abidin, SZ (Author), Cheah, PS (Author), Habib, O (Author), Hamzah, H (Author), Hassan, Z (Author), Lee, HC (Author), Leong, MPY (Author), Lim, SM (Author), Ling, KH (Author), Moklas, MAM (Author), Nordin, N (Author), Seth, EA (Author), Vidyadaran, S (Author), Yusof, HM (Author)
Format: Article
Language:English
Published: 2021
Subjects:
ACTIVATION
ASTROCYTES
CENTRAL-NERVOUS-SYSTEM
CLINICAL-CHEMISTRY
EFFICACY
JAK2 INHIBITOR
MODULATION
PATHWAY
PERSISTENCE
RESISTANCE
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items